Study will test Symlin-insulin combo for type 1 diabetes

05/10/2011 | San Diego Union-Tribune

Amylin Pharmaceuticals is collaborating with the Juvenile Diabetes Research Foundation to test a combination of injectable Symlin and insulin. The clinical study will evaluate whether the combo therapy is as effective as two separate shots in controlling blood glucose levels among patients with type 1 diabetes, Amylin said.

View Full Article in:

San Diego Union-Tribune

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ